Reduced hypoglycemia risk with insulin glargine - A metaanalysis comparing insulin glargine with human NPH insulin in type 2 diabetes

OBJECTIVE - insulin glargine (LANTUS) is a once-daily basal insulin analog with a smooth 24-h time-action profile that provides effective glycemic control with reduced hypoglycemia risk (particularly nocturnal) compared with NPH insulin in patients with type 2 diabetes. A recent treat-to-target study has shown that more patients on insulin glargine reached HbA(1c) levels <= 7.0% without confirmed nocturnal hypoglycemia compared with NPH insulin. We further assessed the risk for hypoglycemia in a meta-analysis of controlled trials of a similar design for insulin glargine versus once- or twice-daily NPH insulin in adults with type 2 diabetes. RESEARCH DESIGN AND METHODS - All studies were 24-28 weeks long, except one 52-week study, for which interim 20-week data were used. RESULTS - Patient demographics were similar between the insulin glargine (n = 1, 142) and NPH insulin (n = 1,162) groups. The proportion of patients achieving target HbA(1c) (<= 7.0%) was similar between insulin glargine- and NPH insulin-treated patients (30.8 and 32.1%, respectively). There was a consistent significant reduction of hypoglycemia risk associate wit insulin glargine, compared with NPH insulin, in terms of overall symptomatic (11%; P = 0.0006) and nocturnal (26%; P < 0.0001) hypoglycemia. Most notably, the risk of severe hypoglycemia and severe nocturnal hypoglycemia were reduced with insulin glargine by 46% (P = 0.0442) and 59% (P = 0.0231), respectively. CONCLUSIONS - These results confirmed that insulin glargine given once daily reduces the risk of hypoglycemia compared with NPH insulin, which can facilitate more aggressive insulin treatment to a HbA(1c) target of <= 7.0% in patients with type 2 diabetes.